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the prevalence of HIV positivity
among our patients is unknown, a pre-
liminary study from Yangon shows
that the prevalence of drug-resistant
TB among HIV-seropositive and -
seronegative patients is the same
(pers. comm., Myanmar national TB
programs]. To our knowledge, this
report is the first to describe drug-
resistant patterns in M. tuberculosis
isolates from Myanmar.
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Pneumocystis 
carinii vs. 
Pneumocystis 
jiroveci: Another 
Misnomer 
(Response to 
Stringer et al.)
To the Editor: The proposal by
Stringer et al. to change the name of
Pneumocystis carinii found in humans
to Pneumocystis jiroveci requires criti-
cal consideration (1). First, their ratio-
nale for the choice of Jírovec is not
compelling. Principle III of the Inter-
national Code of Botanical Nomencla-
ture (ICBN) states: “the nomenclature
of a taxonomic group is based upon
priority of publication” (2). Jírovec’s
publication in 1952 was not the first to
report  P. carinii infection in human
lungs. In 1942, two Dutch investiga-
tors, van der Meer and Brug,
described  P. carinii as the infecting
organism in a 3-month-old infant with
congenital heart disease and in 2 of
104 autopsy cases (a 4-month-old
infant and a 21-year-old adult) (3).
Their description, photomicrographs,
and drawings of P. carinii are
unequivocal. They also described the
typical “honeycomb” patterns in alve-
oli. In 1951, Dr. Josef Vanek at Karls-
Universität in Praha, Czechoslovakia,
reported his study of lung sections
from 16 children with interstitial
pneumonia and demonstrated that the
disease was caused by P. carinii (4).
Vanek notes in his report, “In man the
parasite was for the first time estab-
lished as a cause of pneumonia in a
child by G. Meer and S. L. Brug
(1942).” In 1952, Jírovec reported P.
carinii as the cause of interstitial plas-
macellular pneumonia in neonates (5).
A year later, in a coauthored publica-
tion, Vanek, Jírovec, and J. Lukes
acknowledged and referenced the ear-
lier reports of van der Meer and Brug
and Vanek (6). If principle III is to be
followed, as well as fairness to the
investigators, both van der Meer and
Brug and Vanek hold priority over
Jírovec, assuming the designation of
the species name should be based on
the name of the first person to dis-
cover P. carinii in humans.
The nomenclature of P. carinii has
actually been fraught with errors from
the beginning. In the earliest publica-
tions, Carlos Chagas and Antonio Car-
ini mistook the organism for stages in
the life cycle of trypanosomes. Chagas
placed it in a new genus, Schizotry-
panum (7,8). In 1912, Delanoë and
Delanoë at the Pasteur Institute in
Paris published the first description of
the organism as a new entity unrelated
to trypanosomes (9). They proposed
the name “Pneumocystis carinii” as a
tribute to Carini. The Delanoë paper
has remained unchallenged as the
original description of P. carinii. Both
Chagas and Carini later acknowledged
their errors and the validity of the Del-
anoës’ conclusion. By current ICBN
principles,  P. carinii is acceptable
nomenclature because the authors of
the first publication proposed the
name of Carini, rather than their own.
In addition, changing the name to
P. jiroveci will create confusion in
clinical medicine where the name P.
carinii has served physicians and
microbiologists well for over half aEmerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 277
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century. I was moved to write this let-
ter because of a call from a knowl-
edgeable oncologist asking for
information on “the new strain of P.
carinii that has just been reported
from the Centers for Disease Control
and Prevention,” referring to the
report by Stringer et al (1).
AIDS patients are well informed
about P. carinii pneumonia and avidly
monitor medical news about their dis-
ease. Without doubt, the name change
will cause confusion and undue anxi-
ety among the many thousands of
HIV-infected patients who attend clin-
ics. Health-care workers will have an
added burden of explaining why the
name was changed, but the organism
and infection are unchanged. Also,
versions of the pronunciation of
jiroveci (yee row vet zee) by Ameri-
can patients, physicians, and health-
care workers will be interesting to
hear.
The tone of the article by Stringer
et al. implies that the change of P. car-
inii to P. jiroveci is final, which is not
the case. The nomenclature of fungi is
governed by ICBN under the auspices
of the International Botanical Con-
gress and is not based solely on
molecular genetics. Neither P. carinii
nor P. jiroveci have been submitted for
ICBN scrutiny. In another paper,
Stringer et al. outline the mechanics
for submission, but indicate that no
application has been submitted for
their proposal (10). In fact, P. carinii
has not been acknowledged as a fun-
gus by ICBN or any other authorita-
tive taxonomic system. Only when
nomenclature is registered in ICBN,
can a name be referred to as “formally
accepted.” In the meantime, the work-
able terminology proposed earlier by
Stringer et al. in 1994 (11) will suffice
for clinical use.
Walter T. Hughes*
*St. Jude Children’s Research Hospital,
Memphis, Tennessee, USA
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A New Name 
(Pneumocystis 
jiroveci) for 
Pneumocystis from 
Humans (Response 
to Hughes)
Reply to W.T. Hughes: We appre-
ciate Dr. Hughes’ letter of concern
regarding our article endorsing the
name Pneumocystis jiroveci (1). When
working with well-known disease
agents and syndromes, these types of
changes are more difficult to adopt
because of the effect they have on
daily communication, patient care,
record keeping, and other important
routines of health-care providers.
However, in this case, new informa-
tion and understanding dictate that a
change be made.
For some time, scientists have
known that humans are infected by a
particular species of Pneumocystis and
that this species does not infect other
host species. In recognition of these
facts, Frenkel named the human
pathogen Pneumocystis jiroveci, using
the procedure prescribed by the Inter-
national Code of Botanical Nomencla-
ture (ICBN) (2). Although Dr. Hughes
raised a number of issues, none justi-
fies rejecting the new, valid name. 
Dr. Hughes suggested that the
name  P. jiroveci is incorrect on the
basis of principal III of ICBN, which
holds that “the nomenclature of a tax-
onomic group is based upon priority
of publication.” He indicated that
Jírovec was not the first investigator to
report  Pneumocystis in humans.
Although this situation may be the
case, principal III has not been vio-
lated because “priority of publica-
tion” refers to the time when a name is
validly published, not to the time
when an organism is first described.
The name P. jiroveci was validly pub-
lished in 1999, and this name therefore
has priority. To be valid, all of the fol-
lowing steps must be completed: a